Cargando…
Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer
BACKGROUND: Breast cancer is one of the most common forms of cancer in the United States, with approximately 10% of newly diagnosed patients presenting with metastatic disease. Limited therapy options make the successful treatment of metastatic breast cancer (MBC) difficult. Current treatment option...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437736/ https://www.ncbi.nlm.nih.gov/pubmed/19610679 http://dx.doi.org/10.18553/jmcp.2009.15.6.467 |